# Novel Molecular Mechanisms of Neuromuscular Disease: Implications for Therapy Lady Margaret Hall, Oxford, UK September 16 – 18, 2013

Please note: All General Sessions are in the Simpkins Lee Theatre. Ancillary Meetings will be held in the Old Library or Mary O'Brien Rooms. Poster session presentations will be in the Simpkins Lee Theatre. Posters will be displayed in the Monson Room.

### **TENTATIVE AGENDA (Updated 7/31/2013)**

#### Sunday, September 15, 2013

Arrival at Lady Margaret Hall for those attending ancillary workshops/meetings on Monday

7:00 – 8:00 p.m. Dinner for Guests Attending Ancillary Meetings on Monday

Deneke Dining Hall

#### Day 1: Monday, September 16, 2013

7:30 – 8:00 AM	Buffet Breakfast Deneke Dining Hall
8:00 AM - 5:00 PM	<b>Ancillary Meetings/Workshops</b> (Multicenter investigator groups [open to all attendees; Trainees encouraged to participate])
8:00 – 9:00	Methotrexate Ancillary Meeting (Richard Barohn and Laura Herbelin) Old Library
9:00 – 10:00	Rasagiline Ancillary Meeting (Richard Barohn and Laura Herbelin) Old Library
11:00 – 12:00	<b>The International IBM Consortium Genetic Study Ancillary Meeting</b> (Pedro Machado and Michael Hanna) Old Library
12:00 – 1:30	Lunch for Ancillary Study Participants Deneke Dining Hall
	MSG Executive Committee Meeting over Lunch Photos will be taken of Executive Committee Members Jerwood Room
1:30 – 2:30	<b>CINCH Ancillary Meeting</b> (Richard Barohn, Robert Griggs, Michael Hanna) Old Library
2:30 – 3:00	Poster Session Set-Up Monson Room

# Novel Molecular Mechanisms of Neuromuscular Disease: Implications for Therapy Lady Margaret Hall, Oxford, UK September 16 – 18, 2013

Please note: All General Sessions are in the Simpkins Lee Theatre. Ancillary Meetings will be held in the Old Library or Mary O'Brien Rooms. Poster session presentations will be in the Simpkins Lee Theatre. Posters will be displayed in the Monson Room.

# **TENTATIVE AGENDA (Updated 7/31/2013)**

2:30 – 3:30 Orphazyme Ancillary Meeting (Richard Barohn and Laura Herbelin) Old Library  3:30 – 5:00 Update on Current/Planned MSG Trials (all MSG meeting attendees encouraged to attend) Simpkins Lecture Hall  3:30 – 3:35 FOR – DMD Study (Griggs)  3:40 – 3:50 Arimoclomol IBM (Orphazyme) Study (Dimachkie)  3:50 – 4:00 Methotrexate Study (Barohn)  4:00 – 4:10 Rasagiline Study (Barohn)  4:10 – 4:20 International IBM Consoritium (Hanna/Macado)  4:20 – 4:30 FSHD (Griggs)  4:30 – 4:40 Epitome (Benetar)  4:40 – 4:50 Inherited Neuropathy Consortium (Shy)  4:50 – 5:00 HYP HOP (Griggs)  5:00 – 6:30 PM Brief Presentations and Poster Session I Moderators: Mazen Dimachkie (University of Kansas) and Carlayne Jacks (University of Texas Health Science Center)	
encouraged to attend) Simpkins Lecture Hall  3:30 – 3:35 FOR – DMD Study (Griggs)  3:40 – 3:50 Arimoclomol IBM (Orphazyme) Study (Dimachkie)  3:50 – 4:00 Methotrexate Study (Barohn)  4:00 – 4:10 Rasagiline Study (Barohn)  4:10 – 4:20 International IBM Consoritium (Hanna/Macado)  4:20 – 4:30 FSHD (Griggs)  4:30 – 4:40 Epitome (Benetar)  4:40 – 4:50 Inherited Neuropathy Consortium (Shy)  4:50 – 5:00 HYP HOP (Griggs)  5:00 – 6:30 PM  Brief Presentations and Poster Session I Moderators: Mazen Dimachkie (University of Kansas) and Carlayne Jacks (University of Texas Health Science Center)	
Simpkins Lecture Hall  3:30 – 3:35 FOR – DMD Study (Griggs)  3:40 – 3:50 Arimoclomol IBM (Orphazyme) Study (Dimachkie)  3:50 – 4:00 Methotrexate Study (Barohn)  4:00 – 4:10 Rasagiline Study (Barohn)  4:10 – 4:20 International IBM Consoritium (Hanna/Macado)  4:20 – 4:30 FSHD (Griggs)  4:30 – 4:40 Epitome (Benetar)  4:40 – 4:50 Inherited Neuropathy Consortium (Shy)  4:50 – 5:00 HYP HOP (Griggs)  5:00 – 6:30 PM  Brief Presentations and Poster Session I Moderators: Mazen Dimachkie (University of Kansas) and Carlayne Jacks (University of Texas Health Science Center)	
3:30 – 3:35  FOR – DMD Study (Griggs)  3:40 – 3:50  Arimoclomol IBM (Orphazyme) Study (Dimachkie)  3:50 – 4:00  Methotrexate Study (Barohn)  4:00 – 4:10  Rasagiline Study (Barohn)  4:10 – 4:20  International IBM Consoritium (Hanna/Macado)  4:20 – 4:30  FSHD (Griggs)  4:30 – 4:40  Epitome (Benetar)  4:40 – 4:50  Inherited Neuropathy Consortium (Shy)  4:50 – 5:00  HYP HOP (Griggs)  5:00 – 6:30 PM  Brief Presentations and Poster Session I Moderators: Mazen Dimachkie (University of Kansas) and Carlayne Jacks (University of Texas Health Science Center)	
3:40 – 3:50 Arimoclomol IBM (Orphazyme) Study (Dimachkie)  3:50 – 4:00 Methotrexate Study (Barohn)  4:00 – 4:10 Rasagiline Study (Barohn)  4:10 – 4:20 International IBM Consoritium (Hanna/Macado)  4:20 – 4:30 FSHD (Griggs)  4:30 – 4:40 Epitome (Benetar)  4:40 – 4:50 Inherited Neuropathy Consortium (Shy)  4:50 – 5:00 HYP HOP (Griggs)  5:00 – 6:30 PM  Brief Presentations and Poster Session I Moderators: Mazen Dimachkie (University of Kansas) and Carlayne Jacks (University of Texas Health Science Center)	
3:50 – 4:00 Methotrexate Study (Barohn) 4:00 – 4:10 Rasagiline Study (Barohn) 4:10 – 4:20 International IBM Consoritium (Hanna/Macado) 4:20 – 4:30 FSHD (Griggs) 4:30 – 4:40 Epitome (Benetar) 4:40 – 4:50 Inherited Neuropathy Consortium (Shy) 4:50 – 5:00 HYP HOP (Griggs)  5:00 – 6:30 PM  Brief Presentations and Poster Session I Moderators: Mazen Dimachkie (University of Kansas) and Carlayne Jacks (University of Texas Health Science Center)	
4:00 – 4:10 Rasagiline Study (Barohn)  4:10 – 4:20 International IBM Consoritium (Hanna/Macado)  4:20 – 4:30 FSHD (Griggs)  4:30 – 4:40 Epitome (Benetar)  4:40 – 4:50 Inherited Neuropathy Consortium (Shy)  4:50 – 5:00 HYP HOP (Griggs)  5:00 – 6:30 PM Brief Presentations and Poster Session I Moderators: Mazen Dimachkie (University of Kansas) and Carlayne Jacks (University of Texas Health Science Center)	
4:10 – 4:20 International IBM Consoritium (Hanna/Macado)  4:20 – 4:30 FSHD (Griggs)  4:30 – 4:40 Epitome (Benetar)  4:40 – 4:50 Inherited Neuropathy Consortium (Shy)  4:50 – 5:00 HYP HOP (Griggs)  5:00 – 6:30 PM Brief Presentations and Poster Session I Moderators: Mazen Dimachkie (University of Kansas) and Carlayne Jacks (University of Texas Health Science Center)	
4:20 – 4:30 FSHD (Griggs)  4:30 – 4:40 Epitome (Benetar)  4:40 – 4:50 Inherited Neuropathy Consortium (Shy)  4:50 – 5:00 HYP HOP (Griggs)  5:00 – 6:30 PM Brief Presentations and Poster Session I Moderators: Mazen Dimachkie (University of Kansas) and Carlayne Jacks (University of Texas Health Science Center)	
4:30 – 4:40 Epitome (Benetar)  4:40 – 4:50 Inherited Neuropathy Consortium (Shy)  4:50 – 5:00 HYP HOP (Griggs)  5:00 – 6:30 PM Brief Presentations and Poster Session I Moderators: Mazen Dimachkie (University of Kansas) and Carlayne Jacks (University of Texas Health Science Center)	
4:40 – 4:50 Inherited Neuropathy Consortium (Shy)  4:50 – 5:00 HYP HOP (Griggs)  5:00 – 6:30 PM  Brief Presentations and Poster Session I Moderators: Mazen Dimachkie (University of Kansas) and Carlayne Jacks (University of Texas Health Science Center)	
4:50 – 5:00 HYP HOP (Griggs)  5:00 – 6:30 PM  Brief Presentations and Poster Session I  Moderators: Mazen Dimachkie (University of Kansas) and Carlayne Jacks (University of Texas Health Science Center)	
5:00 – 6:30 PM  Brief Presentations and Poster Session I  Moderators: Mazen Dimachkie (University of Kansas) and Carlayne Jacks (University of Texas Health Science Center)	
Moderators: Mazen Dimachkie (University of Kansas) and Carlayne Jacks (University of Texas Health Science Center)	
(University of Texas Health Science Center)	
· · · · · · · · · · · · · · · · · · ·	son
Simpkins Lecture Hall	
5:00 – 5:10 <u>Presentation I</u> - Validation of the MRC MRI Diagnostic Score for Inclus	ısion
Body Myositis Jasper Morrow (University College London)	
5:10 – 5:20 Presentation II - A Preliminary Score Tool for the Evaluation of Muscle	le
Biopsies in Patients with Inclusion Body Myositis – Application in a Randomised Placebo-Controlled Clinical Trial	
Pedro Machado (University College London)	

# Novel Molecular Mechanisms of Neuromuscular Disease: Implications for Therapy Lady Margaret Hall, Oxford, UK September 16 – 18, 2013

Please note: All General Sessions are in the Simpkins Lee Theatre. Ancillary Meetings will be held in the Old Library or Mary O'Brien Rooms. Poster session presentations will be in the Simpkins Lee Theatre. Posters will be displayed in the Monson Room.

### **TENTATIVE AGENDA (Updated 7/31/2013)**

Day	1:	Monday,	September	16,	2013	(Continued)
-----	----	---------	-----------	-----	------	-------------

5:20 - 5:30	Presentation III - Cytosolic 5'-Nucleotidase 1A Autoimmunity in Sporadic

**Inclusion Body Myositis** 

Steven Greenberg (Harvard University)

5:30 – 6:40 Poster Session with hors d'oeuvres & cash bar

Monson Room

6:40 – 7:00 Travel to Magdalen College via Motor Coach

7:30 - 8:30 PM Dinner

Magdalen College - Hall

8:30 PM Keynote Speaker:

David Hilton-Jones (Oxford) NMD: A Historical Perspective

#### Day 2: Tuesday, September 17, 2013

7:30 – 8:00 AM	Buffet Breakfast for New Members/Guests [open to all]
----------------	---

Jerwood Room

Moderators: Richard Barohn (University of Kansas), Robert Griggs

(University of Rochester)

7:30 – 8:00 AM Breakfast

Deneke Dining Room

8:00 – 8:10 AM Welcome/General Session

Simpkins Lee Theatre

Robert C. Griggs (University of Rochester), Mary Reilly (University College

London) and Gil Wolfe (University at Buffalo)

8:10 AM – 8:30 PM Novel Molecular Mechanisms: Implications for Therapy Development

Session I: Hereditary Myopathies

Moderators: Michael Hanna (University College London) and Kate Bushby

(Newcastle University)

8:10 – 8:50 Calpainopathy: Human Gene Therapies

Isabelle Richard (Genethon)

# Novel Molecular Mechanisms of Neuromuscular Disease: Implications for Therapy Lady Margaret Hall, Oxford, UK September 16 – 18, 2013

Please note: All General Sessions are in the Simpkins Lee Theatre. Ancillary Meetings will be held in the Old Library or Mary O'Brien Rooms. Poster session presentations will be in the Simpkins Lee Theatre. Posters will be displayed in the Monson Room.

# **TENTATIVE AGENDA (Updated 7/31/2013)**

#### Day 2: Tuesday, September 17, 2013 (Continued)

8:50 – 9:30	Molecular Therapies for Neuromuscular Diseases Jerry Mendell (Nationwide Children's)
9:30 – 10:00	OPMD Bernard Brais (University of Montreal)
10:00 – 10:20	Discussion
10:20 - 10:50	Break
10:50 – 11:30	FSHD Rabi Tawil (University of Rochester)
11:30 – 12:10	Dystrophinopathies Francesco Muntoni (University College London)
12:10 – 12:50	Myotonic Dystrophy Charles Thornton (University of Rochester)
12:50 – 1:10	Discussion
1:10 – 2:10 PM	Lunch Deneke Dining Hall
1:10 – 2:10	FOR – DMD Ancillary Meeting (Robert Griggs and Kate Bushby) TBD
2:10 – 5:30 PM	Overcoming Hurdles of Developing and Performing Clinical Trials – Panel Format Moderators: Michael McDermott (University of Rochester) and Gil Wolfe (University of Buffalo)
2:10 – 3:00	Neuro NEXT and NMD: Update Petra Kaufmann (NINDS)
	What is 'Adequate Rationale' to Initiate a Trial? [Spoiler Alert: No Holy Grail Here, Only Equipoise—Good, Bias—Bad] John Porter (NINDS)

# Novel Molecular Mechanisms of Neuromuscular Disease: Implications for Therapy Lady Margaret Hall, Oxford, UK September 16 – 18, 2013

Please note: All General Sessions are in the Simpkins Lee Theatre. Ancillary Meetings will be held in the Old Library or Mary O'Brien Rooms. Poster session presentations will be in the Simpkins Lee Theatre. Posters will be displayed in the Monson Room.

#### **TENTATIVE AGENDA (Updated 7/31/2013)**

#### Day 2: Tuesday, September 17, 2013 (Continued)

#### **TBD**

Valerie Cwik (Muscular Dystrophy Association)

#### **Tentative**

Glen Nuckolls (NIAMS)

3:00 – 4:00 Clinical Trial #1: Translating Bumetanide to the PP Clinical Trial Theatre

Presenters: Michael Hanna (University of College London) and Jeff Statland

(University of Rochester)

Discussants: Jaya Trivedi (University of Texas Southwestern), Richard Barohn (University of Kansas), Michael McDermott (University of Rochester) (University College London), Gil I. Wolfe (University of Buffalo).

# Clinical Trial #2: Clinical Trials in CMT: The Past and Present and Directions for the Future

Presenter: Michael Shy (University of Iowa)

Discussants: Steven Scherer (University of Pennsylvania), Mary Reilly (University College London) Michael McDermott (University of Rochester), Gil Wolfe (University of Buffalo) and Scott Evans (Harvard),

4:00 – 5:00 Challenges of Conducting International Multicenter Clinical Trials: The

FOR-DMD Study: A Case Study

Michela Guglieri, Kate Bushby, Kim Hart, Robert Griggs

5:00 – 5:15 Discussion

5:15 – 6:00 Break/Free Time/Informal Discussion

**Poster Session Set-up** 

Monson Room

6:00 – 7:30 PM Brief Presentations and Poster Session II

Moderators: Mazen Dimachkie (University

of Kansas) and Carlayne Jackson (University of Texas Health Science Center)

6:00 – 6:10 Presentation I – Potential Mechanisms in Musk-Myasthenia Gravis

Inga Koneczny (Oxford)

6:10 – 6:20 Presentation II – Characterization of CD4 and CD8 T-Cell Responses in

**MuSK Myasthenia Gravis** 

Donald Sanders (Duke University)

# Novel Molecular Mechanisms of Neuromuscular Disease: Implications for Therapy Lady Margaret Hall, Oxford, UK September 16 – 18, 2013

Please note: All General Sessions are in the Simpkins Lee Theatre. Ancillary Meetings will be held in the Old Library or Mary O'Brien Rooms. Poster session presentations will be in the Simpkins Lee Theatre. Posters will be displayed in the Monson Room.

#### **TENTATIVE AGENDA (Updated 7/31/2013)**

#### Day 2: Tuesday, September 17, 2013 (Continued)

6:20 - 6:30	Presentation III – Results of REVERSE-DBMD: Revatio for Heart Disease in
-------------	--

**Duchenne and Becker Muscular Dystrophy** 

Kathryn Wagner (Kennedy Krieger)

6:30 - 7:30 PM Poster Session with hors d'oeuvres & cash bar

Monson Room

7:30 – 8:30 PM Dinner

Deneke Dining Hall

8:30 PM Keynote Speaker:

Doug Turnbull (Newcastle University)

Mitochondrial Cytopathies Simpkins Lee Theatre

#### Day 3: Wednesday, September 18, 2013

7:00 – 9:00 AM	Checkout in Porter's Lodge (space will be available for luggage storage)
7:30 – 8:00 AM	Breakfast Deneke Dining Hall
8:00 - 8:10 AM	MSG Status Report – Robert Griggs (University of Rochester) Nominations – Carlayne Jackson (University of Texas Health Science Center) Simpkins Lee Theatre
8:10 AM – 6:00 PM	Novel Molecular Mechanisms: Implications for Therapy Development Session II: Hereditary Neuropathies Moderators: Mary Reilly (University College London) and Steve Scherer (University of Pennsylvania)

8:10 – 8:40 Peripheral Demyelination

M. Laura Feltri (University of Buffalo)

8:40 – 9:20 Hereditary Axonopathies

Mary Reilly (University College London)

# Novel Molecular Mechanisms of Neuromuscular Disease: Implications for Therapy Lady Margaret Hall, Oxford, UK September 16 – 18, 2013

Please note: All General Sessions are in the Simpkins Lee Theatre. Ancillary Meetings will be held in the Old Library or Mary O'Brien Rooms. Poster session presentations will be in the Simpkins Lee Theatre. Posters will be displayed in the Monson Room.

# **TENTATIVE AGENDA (Updated 7/31/2013)**

#### Day 3: Wednesday, September 18, 2013 (Continued)

9:20 – 10:00	Connexin 32 Neuropathies Steve Scherer (University of Pennsylvania)
10:00 – 10:20	Discussion
10:20 – 10:50	Break
10:50 – 11:20	Motor Neuron Disease Kevin Talbot (Oxford)
11:20 – 11:50	Neuropathies:Channelopathies David Bennett (Oxford)
11:50 – 12:10	Discussion
12:10 – 12:30	<b>Group Photo</b> Simpkins Lee Theatre or Outside Courtyard
12:30 – 1:10	<b>Lunch</b> Deneke Dining Hall
1:10 – 2:10	Late Breaking News
1:10 - 2:10 2:10 - 4:10	Late Breaking News  Disorders of the NMJ: The View from Oxford  Moderator: Angela Vincent
	Disorders of the NMJ: The View from Oxford
2:10 – 4:10	Disorders of the NMJ: The View from Oxford Moderator: Angela Vincent  Molecular Background to CMS
2:10 - 4:10 2:10 - 2:40	Disorders of the NMJ: The View from Oxford Moderator: Angela Vincent  Molecular Background to CMS David Beeson (Oxford)  CMS: Clinical Perspectives
2:10 - 4:10 2:10 - 2:40 2:40 - 3:10	Disorders of the NMJ: The View from Oxford Moderator: Angela Vincent  Molecular Background to CMS David Beeson (Oxford)  CMS: Clinical Perspectives Jacqueline Palace (Oxford)  Immune-Mediated Mechanisms
2:10 - 4:10 2:10 - 2:40 2:40 - 3:10 3:10 - 3:50	Disorders of the NMJ: The View from Oxford Moderator: Angela Vincent  Molecular Background to CMS David Beeson (Oxford)  CMS: Clinical Perspectives Jacqueline Palace (Oxford)  Immune-Mediated Mechanisms Angela Vincent (Oxford)

# Novel Molecular Mechanisms of Neuromuscular Disease: Implications for Therapy Lady Margaret Hall, Oxford, UK September 16 – 18, 2013

Please note: All General Sessions are in the Simpkins Lee Theatre. Ancillary Meetings will be held in the Old Library or Mary O'Brien Rooms. Poster session presentations will be in the Simpkins Lee Theatre. Posters will be displayed in the Monson Room.

### **TENTATIVE AGENDA (Updated 7/31/2013)**

Day 3: Wednesday, September 18, 2013 (Continued)

6:40 PM Dinner on own

Day 4: Thursday, September 19, 2013

7:00 – 8:00 AM Breakfast

7:00 – 9:00 AM Checkout and Departures